Ensol Biosciences엔솔바이오사이언스

Ensol Biosciences shares have fallen sharply over the past year, and the data holds no current financial results to judge the business by.

Ensol Biosciences is a KONEX-listed peptide drug developer with clinical programs in degenerative disc disease, knee osteoarthritis, and cancer, and it earns revenue from technology licensing and a veterinary osteoarthritis product. The stock closed at ₩7,830 on 2026-10-23, close to its 52-week low of ₩7,820 and down 47.1% over one year, with a market value of ₩112.6B. The data contains no annual or trailing financial statements, valuation multiples, or dividend history beyond a 0% yield, so the current financial position cannot be assessed from this pack.

What stands out

• The share price is near its 52-week low of ₩7,820, after a 52-week high of ₩17,900.
• Returns were -22.7% over one month, -34.3% over three months and -47.1% over one year.
• No annual financials, trailing results or valuation multiples are included, so profitability and cash position are unknown here.
• Recent filings include a rights offering decided in June 2026 and a third-party allotment rights offering whose results were filed on 2026-06-19.
• Over the past 20 days, retail investors were net sellers of about ₩21.2M, while foreign and institutional net flows were zero and foreign ownership is 0%.
• No recent news headlines were included in the data.

What to watch

• Upcoming periodic financial filings, which would be the first real test of revenue and losses in this pack.
• Clinical trial progress for P2K, E1K and C1K, which the company profile names as its core programs but the data does not detail.
• Further share issuance or major holder changes, since the June rights offering and recent 5%+ holding reports could affect the share count and ownership.